'Moonshot' Opportunities: Dx Reimbursement, Radiation Therapy Among Medtech Focal Points
This article was originally published in The Gray Sheet
Executive Summary
Personalized-medicine advocates say Vice President Biden's "Cancer Moonshot" initiative is a great opportunity, but it should be putting more focus on the importance of Medicare policies in driving cancer innovation. There is also a push in the medtech space to raise the profile of radiation therapy as a central tool for treating cancer.
You may also be interested in...
US House Would Boost NIH Spending By $2Bn, Support Precision Medicine, BRAIN Initiative, Cybersecurity Funds
The US National Institutes of Health would get a 5% raise of $2bn under a 2020 budget increase to $41.1bn, spending that would go to boost precision medicine research, the BRAIN Initiative, Cancer Moonshot, cybersecurity and other important programs.
US FDA: 510(k)-Exempt Class II Devices Should Withdraw Applications
In line with the 21st Century Cures Act, US FDA has finalized a list of class II devices that will no longer need pre-market notification to get to market. Also, check out our updated Cures Act implementation table.
21st Century Cures Implementation: Device Provision Updates
Dozens of reforms impacting the medtech sector were signed into law Dec. 13, 2016, in the 21st Century Cures Act. Here's a breakdown of where things stand in the implementation of key provisions.